Rationale for combining immunotherapy with chemotherapy

Immunotherapy

Volumn 7, Issue 3, 2015, Pages 309-316

  Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

checkpoint inhibitors; chemotherapy; cytokines; immunotherapy; potential synergy; regulatory and suppressor cell inhibitors; vaccines

Indexed keywords

CANCER VACCINE; IPILIMUMAB; LENALIDOMIDE; PNEUMOCOCCUS VACCINE; POMALIDOMIDE; THALIDOMIDE; ZOLEDRONIC ACID;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; TUMOR IMMUNITY; ANIMAL; CHEMORADIOTHERAPY; DRUG THERAPY; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84925723321     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.111     Document Type: Review

References (71)

1. Browning M, Dalgleish AG. Introduction and historical perspective. In: Tumour Immunology. Sikora K, Dalgleish AG, Browning M (Eds). Cambridge University Press, London, UK (1996).
2. Ward S, Dalgleish A. Therapeutic cancer vaccines. Vaccine 25(Suppl. 2), B1-B3 (2007).
3. Ward S, Copier J, Dalgleish A. Technical challenges facing therapeutic cancer vaccines. Curr. Opin. Drug Discov. Dev. 11, 168-177 (2008).
4. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur. J. Cancer 49, 2965-2967 (2013).
5. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat. Rev. Cancer 5, 397-405 (2005).
6. Thariat J, Boudabous M. [The abscopal effect, synergy between immunotherapy and radiotherapy]. Bull. Cancer 100, 1071 (2013).
7. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr. Opin. Immunol. 27C, 26-32 (2014).
8. Chapman PB. Melanoma vaccines. Semin. Oncol. 34, 516-523 (2007).
9. Dawson NA, Roesch EE. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Expert. Opin. Biol. Ther. 14, 709-719 (2014).
10. Dalgleish AG. Therapeutic cancer vaccines: why so few randomised Phase III studies reflect the initial optimism of Phase II studies. Vaccine 29, 8501-8505 (2011).
11. Irie T, Tsujii M, Tsuji S et al. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int. J. Cancer 121, 878-883 (2007).
12. Cadogan M, Dalgleish AG. Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin. Med. 8, 267-271 (2008).
13. Dalgleish AG. Viruses and cancer. Br. Med. Bull. 47, 21-46 (1991).
14. Heriot AG, Marriott JB, Cookson S et al. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82, 1009-1012 (2000).
15. Evans C, Morrison I, Heriot AG et al. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br. J. Cancer 94, 1412-1419 (2006).
16. Clerici M, Ferrario E, Trabattoni D et al. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur. J. Cancer 30A, 1464-1470 (1994).
17. Zou JP, Morford LA, Chougnet C et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162, 4882-4892 (1999).
18. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 85, 473-483 (2001).
19. Dalgleish AG, O'Byrne K. Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat. Res. 130, 1-38 (2006).
20. Lee CS, McNamara D, O'Morain CA. Aspirin as a chemoprevention agent for colorectal cancer. Curr. Drug Metab. 13, 1313-1322 (2012).
21. Greenberg ER, Baron JA, Freeman DH Jr et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl Cancer Inst. 85, 912-916 (1993).
22. Labayle D, Fischer D, Vielh P et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635-639 (1991).
23. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment. Pharmacol. Ther. 24, 1163-1177 (2006).
24. Qiu B, Zhang D, Wang C et al. IL-10 and TGF-beta2 are overexpressed in tumor spheres cultured from human gliomas. Mol. Biol. Rep. 38, 3585-3591 (2011).
25. Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res. 66, 4488-4495 (2006).
26. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739-752 (2013).
27. Kan S, Hazama S, Maeda K et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 32, 5363-5369 (2012).
28. Le HK, Graham L, Cha E et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9, 900-909 (2009).
29. Fryer RA, Galustian C, Dalgleish AG. Recent advances and developments in treatment strategies against pancreatic cancer. Curr. Clin. Pharmacol. 4, 102-112 (2009).
30. Lien K, Georgsdottir S, Sivanathan L et al. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur. J. Cancer 49, 3387-3395 (2013).
31. Gross TG. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res. 159, 96-103 (2002).
32. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
33. Penel N, Clisant S, Dansin E et al. Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br. J. Cancer 102, 1207-1212 (2010).
34. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
35. June CH, Maus MV, Plesa G et al. Engineered T cells for cancer therapy. Cancer Immunol. Immunother. 63, 969-975 (2014).
36. Lieberman R, Wybran J, Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer 35, 756-777 (1975).
37. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9, 532-562 (1996).
38. Stanford JL, Bahr GM, Rook GA et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 71, 87-93 (1990).
39. Lahey T, Arbeit RD, Bakari M et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a Phase III study in Tanzania. Vaccine 28, 7652-7658 (2010).
40. von Reyn CF, Mtei L, Arbeit RD et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24, 675-685 (2010).
41. Maraveyas A, Baban B, Kennard D et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol. 10, 817-824 (1999).
42. Nicholson S, Guile K, John J et al. A randomized Phase II trial of SRL172 (Mycobacterium vaccae) +/-low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res. 13, 389-393 (2003).
43. Deehan DJ, Heys SD, Ashby J, Eremin O. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease. Eur. J. Surg. Oncol. 21, 16-22 (1995).
44. Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26, 4984-4990 (2008).
45. O'Brien ME, Anderson H, Kaukel E et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann. Oncol. 15, 906-914 (2004).
46. Stanford JL, Stanford CA, O'Brien ME, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer 44, 224-227 (2008).
47. Stebbing J, Dalgleish A, Gifford-Moore A et al. An intra-patient placebo-controlled Phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann. Oncol. 23, 1314-1319 (2012).
48. Cananzi FC, Mudan S, Dunne M et al. Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Hum. Vaccin. Immunother. 9, 2427-2433 (2013).
49. Petrella T, Verma S, Spithoff K et al. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin. Oncol. (R. Coll. Radiol.) 24, 413-423 (2012).
50. Amin A, White RL Jr. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies? Oncology (Williston Park) 27, 680-691 (2013).
51. Atkins MB. Interleukin-2: clinical applications. Semin. Oncol. 29, 12-17 (2002).
52. Movva S, Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert. Opin. Biol. Ther. 9, 231-241 (2009).
53. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert. Opin. Biol. Ther. 13, 847-861 (2013).
54. Batus M, Waheed S, Ruby C et al. Optimal management of metastatic melanoma: current strategies and future directions. Am. J. Clin. Dermatol. 14, 179-194 (2013).
55. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
56. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
57. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007).
58. Ollila DW, Kelley MC, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin. Surg. Oncol. 14, 328-336 (1998).
59. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
60. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
61. Kepp O, Tesniere A, Schlemmer F et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14, 364-375 (2009).
62. Vacchelli E, Aranda F, Eggermont A et al. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 3, e27878 (2014).
63. Naoe M, Ogawa Y, Takeshita K et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol. Res. 18, 493-501 (2010).
64. Dieli F, Vermijlen D, Fulfaro F et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450-7457 (2007).
65. Fowler DW, Copier J, Wilson N et al. Mycobacteria activate gammadelta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol. Immunother. 61, 535-547 (2012).
66. Dalgleish A, Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol. 6, 1479-1484 (2010).
67. Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 90, 955-961 (2004).
68. Dredge K, Marriott JB, Todryk SM et al. Protective antitumor Immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168, 4914-4919 (2002).
69. Noonan K, Rudraraju L, Ferguson A et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin. Cancer Res. 18, 1426-1434 (2012).
70. Maus MV, Fraietta JA, Levine BL et al. Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32, 189-225 (2014).
71. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).